Swedish researchers find low daily dose can halve risk in post-surgery patients with specific gene mutations
A daily dose of aspirin can substantially reduce the risk of some colorectal cancers returning after surgery, according to a major trial into the protective effects of the everyday painkiller.
Swedish researchers found that people who took a low daily dose of aspirin after having their tumour removed were half as likely to have their cancer return over the next three years than patients who took a placebo.